Cargando…
Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers
Currently, there is no single test for multiple sclerosis (MS). Diagnosis is confirmed through clinical evaluation, abnormalities revealed by magnetic resonance imaging (MRI), and analysis of cerebrospinal fluid (CSF) chemistry. The early and accurate diagnosis of the disease, monitoring of progress...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851054/ https://www.ncbi.nlm.nih.gov/pubmed/17124343 http://dx.doi.org/10.1155/2006/670439 |
_version_ | 1782294214727434240 |
---|---|
author | O’Connor, Kevin C. Roy, Sushmita Mimi Becker, Christopher H. Hafler, David A. Kantor, Aaron B. |
author_facet | O’Connor, Kevin C. Roy, Sushmita Mimi Becker, Christopher H. Hafler, David A. Kantor, Aaron B. |
author_sort | O’Connor, Kevin C. |
collection | PubMed |
description | Currently, there is no single test for multiple sclerosis (MS). Diagnosis is confirmed through clinical evaluation, abnormalities revealed by magnetic resonance imaging (MRI), and analysis of cerebrospinal fluid (CSF) chemistry. The early and accurate diagnosis of the disease, monitoring of progression, and gauging of therapeutic intervention are important but elusive elements of patient care. Moreover, a deeper understanding of the disease pathology is needed, including discovery of accurate biomarkers for MS. Herein we review putative biomarkers of MS relating to neurodegeneration and contributions to neuropathology, with particular focus on autoimmunity. In addition, novel assessments of biomarkers not driven by hypotheses are discussed, featuring our application of advanced proteomics and metabolomics for comprehensive phenotyping of CSF and blood. This strategy allows comparison of component expression levels in CSF and serum between MS and control groups. Examination of these preliminary data suggests that several CSF proteins in MS are differentially expressed, and thus, represent putative biomarkers deserving of further evaluation. |
format | Online Article Text |
id | pubmed-3851054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38510542013-12-18 Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers O’Connor, Kevin C. Roy, Sushmita Mimi Becker, Christopher H. Hafler, David A. Kantor, Aaron B. Dis Markers Other Currently, there is no single test for multiple sclerosis (MS). Diagnosis is confirmed through clinical evaluation, abnormalities revealed by magnetic resonance imaging (MRI), and analysis of cerebrospinal fluid (CSF) chemistry. The early and accurate diagnosis of the disease, monitoring of progression, and gauging of therapeutic intervention are important but elusive elements of patient care. Moreover, a deeper understanding of the disease pathology is needed, including discovery of accurate biomarkers for MS. Herein we review putative biomarkers of MS relating to neurodegeneration and contributions to neuropathology, with particular focus on autoimmunity. In addition, novel assessments of biomarkers not driven by hypotheses are discussed, featuring our application of advanced proteomics and metabolomics for comprehensive phenotyping of CSF and blood. This strategy allows comparison of component expression levels in CSF and serum between MS and control groups. Examination of these preliminary data suggests that several CSF proteins in MS are differentially expressed, and thus, represent putative biomarkers deserving of further evaluation. IOS Press 2006 2006-11-15 /pmc/articles/PMC3851054/ /pubmed/17124343 http://dx.doi.org/10.1155/2006/670439 Text en Copyright © 2006 Hindawi Publishing Corporation. |
spellingShingle | Other O’Connor, Kevin C. Roy, Sushmita Mimi Becker, Christopher H. Hafler, David A. Kantor, Aaron B. Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers |
title | Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers |
title_full | Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers |
title_fullStr | Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers |
title_full_unstemmed | Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers |
title_short | Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers |
title_sort | comprehensive phenotyping in multiple sclerosis: discovery based proteomics and the current understanding of putative biomarkers |
topic | Other |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851054/ https://www.ncbi.nlm.nih.gov/pubmed/17124343 http://dx.doi.org/10.1155/2006/670439 |
work_keys_str_mv | AT oconnorkevinc comprehensivephenotypinginmultiplesclerosisdiscoverybasedproteomicsandthecurrentunderstandingofputativebiomarkers AT roysushmitamimi comprehensivephenotypinginmultiplesclerosisdiscoverybasedproteomicsandthecurrentunderstandingofputativebiomarkers AT beckerchristopherh comprehensivephenotypinginmultiplesclerosisdiscoverybasedproteomicsandthecurrentunderstandingofputativebiomarkers AT haflerdavida comprehensivephenotypinginmultiplesclerosisdiscoverybasedproteomicsandthecurrentunderstandingofputativebiomarkers AT kantoraaronb comprehensivephenotypinginmultiplesclerosisdiscoverybasedproteomicsandthecurrentunderstandingofputativebiomarkers |